eFFECTOR Therapeutics, Inc.

OTCPK:EFTR Stock Report

Market Cap: US$2.4k

eFFECTOR Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for eFFECTOR Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Sep 14

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics (NASDAQ:EFTR) on Wednesday said it had dosed the first patient in the second cohort of its phase 1b clinical trial of its investigational cancer therapy zotatifin for the potential treatment of COVID-19. The early-stage trial is assessing the safety and antiviral activity of a single dose of zotatifin in patients with mild to moderate COVID, and is being conducted in collaboration with the University of California, San Francisco, EFTR said in a statement. The trial is being conducted using a $5M cooperative agreement sponsored by the government-led Defense Advanced Research Projects Agency. The dosing of the first patient in the second cohort follows a positive recommendation of an independent data safety board which reviewed data from the first dose cohort, EFTR said. EFTR stock marginally higher in morning trading.
Seeking Alpha • Aug 09

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics press release (NASDAQ:EFTR): Q2 GAAP EPS of -$0.17. Grant Revenue of $2.01M (+191.3% Y/Y). The company had cash and cash equivalents, and short-term investments totaling $41.0 million as of June 30, 2022, compared to $45.7 million in cash and cash equivalents as of March 31, 2022
Seeking Alpha • Sep 12

eFFECTOR: Developing New Class Of Cancer Therapies

eFFECTOR Therapeutics is pioneering the development of a new class of oncology drugs known as STRIs. The STRI therapy is also being evaluated for COVID-19 at UCSF under a DARPA grant. The company’s stock commenced trading on Nasdaq on 8/26/2021 after merger with SPAC Locust Walk Acquisition Corp. (LWAC).

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as eFFECTOR Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:EFTR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2024N/A-35-29-29N/A
12/31/2023N/A-36-30-30N/A
9/30/20231-36-31-31N/A
6/30/20232-37-31-31N/A
3/31/20234-36-27-27N/A
12/31/20224-23-26-26N/A
9/30/202236-24-24N/A
6/30/2022324-25-25N/A
3/31/2022125-26-26N/A
12/31/2021116-25-25N/A
9/30/20211-4-28-27N/A
6/30/20211-20-26-26N/A
3/31/202116-7-8-8N/A
12/31/20204201414N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EFTR's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if EFTR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if EFTR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if EFTR's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if EFTR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EFTR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/21 22:34
End of Day Share Price 2026/05/21 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

eFFECTOR Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Robert BurnsH.C. Wainwright & Co.
Mara GoldsteinMizuho Securities USA LLC